An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma

Version 2.0

Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie Fecher, Thomas F. Gajewski, Brian Gastman, David H. Lawson, Jose Lutzky, David F. McDermott, Kim A. Margolin, Janice M. Mehnert, Anna C. Pavlick, Jon M. Richards, Krista M. Rubin, William Sharfman, Steven Silverstein, Craig L. Slingluff & 8 others Vernon K. Sondak, Ahmad A. Tarhini, John A. Thompson, Walter J. Urba, Richard L. White, Eric Whitman, F. Stephen Hodi, Howard L. Kaufman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patients with melanoma. However, prospective data to support evidence-based clinical decisions with respect to the optimal schedule and sequencing of immunotherapy and targeted agents, how best to manage emerging toxicities and when to stop treatment are not yet available. Methods: To address this knowledge gap, the Society for Immunotherapy of Cancer (SITC) Melanoma Task Force developed a process for consensus recommendations for physicians treating patients with melanoma integrating evidence-based data, where available, with best expert consensus opinion. The initial consensus statement was published in 2013, and version 2.0 of this report is an update based on a recent meeting of the Task Force and extensive subsequent discussions on new agents, contemporary peer-reviewed literature and emerging clinical data. The Academy of Medicine (formerly Institute of Medicine) clinical practice guidelines were used as a basis for consensus development with an updated literature search for important studies published between 1992 and 2017 and supplemented, as appropriate, by recommendations from Task Force participants. Results: The Task Force considered patients with stage II-IV melanoma and here provide consensus recommendations for how they would incorporate the many immunotherapy options into clinical pathways for patients with cutaneous melanoma. Conclusion: These clinical guidleines provide physicians and healthcare providers with consensus recommendations for managing melanoma patients electing treatment with tumor immunotherapy.

Original languageEnglish (US)
Article number44
JournalJournal for ImmunoTherapy of Cancer
Volume6
Issue number1
DOIs
StatePublished - May 30 2018

Fingerprint

Immunotherapy
Melanoma
Consensus
Skin
Advisory Committees
Neoplasms
Therapeutics
Physicians
National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division
Critical Pathways
Expert Testimony
Drug Combinations
Standard of Care
Practice Guidelines
Health Personnel
Appointments and Schedules
Medicine
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Sullivan, Ryan J. ; Atkins, Michael B. ; Kirkwood, John M. ; Agarwala, Sanjiv S. ; Clark, Joseph I. ; Ernstoff, Marc S. ; Fecher, Leslie ; Gajewski, Thomas F. ; Gastman, Brian ; Lawson, David H. ; Lutzky, Jose ; McDermott, David F. ; Margolin, Kim A. ; Mehnert, Janice M. ; Pavlick, Anna C. ; Richards, Jon M. ; Rubin, Krista M. ; Sharfman, William ; Silverstein, Steven ; Slingluff, Craig L. ; Sondak, Vernon K. ; Tarhini, Ahmad A. ; Thompson, John A. ; Urba, Walter J. ; White, Richard L. ; Whitman, Eric ; Hodi, F. Stephen ; Kaufman, Howard L. / An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma : Version 2.0. In: Journal for ImmunoTherapy of Cancer. 2018 ; Vol. 6, No. 1.
@article{289c811a5c514b9a90176681d9c7836b,
title = "An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: Version 2.0",
abstract = "Background: Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patients with melanoma. However, prospective data to support evidence-based clinical decisions with respect to the optimal schedule and sequencing of immunotherapy and targeted agents, how best to manage emerging toxicities and when to stop treatment are not yet available. Methods: To address this knowledge gap, the Society for Immunotherapy of Cancer (SITC) Melanoma Task Force developed a process for consensus recommendations for physicians treating patients with melanoma integrating evidence-based data, where available, with best expert consensus opinion. The initial consensus statement was published in 2013, and version 2.0 of this report is an update based on a recent meeting of the Task Force and extensive subsequent discussions on new agents, contemporary peer-reviewed literature and emerging clinical data. The Academy of Medicine (formerly Institute of Medicine) clinical practice guidelines were used as a basis for consensus development with an updated literature search for important studies published between 1992 and 2017 and supplemented, as appropriate, by recommendations from Task Force participants. Results: The Task Force considered patients with stage II-IV melanoma and here provide consensus recommendations for how they would incorporate the many immunotherapy options into clinical pathways for patients with cutaneous melanoma. Conclusion: These clinical guidleines provide physicians and healthcare providers with consensus recommendations for managing melanoma patients electing treatment with tumor immunotherapy.",
author = "Sullivan, {Ryan J.} and Atkins, {Michael B.} and Kirkwood, {John M.} and Agarwala, {Sanjiv S.} and Clark, {Joseph I.} and Ernstoff, {Marc S.} and Leslie Fecher and Gajewski, {Thomas F.} and Brian Gastman and Lawson, {David H.} and Jose Lutzky and McDermott, {David F.} and Margolin, {Kim A.} and Mehnert, {Janice M.} and Pavlick, {Anna C.} and Richards, {Jon M.} and Rubin, {Krista M.} and William Sharfman and Steven Silverstein and Slingluff, {Craig L.} and Sondak, {Vernon K.} and Tarhini, {Ahmad A.} and Thompson, {John A.} and Urba, {Walter J.} and White, {Richard L.} and Eric Whitman and Hodi, {F. Stephen} and Kaufman, {Howard L.}",
year = "2018",
month = "5",
day = "30",
doi = "10.1186/s40425-018-0362-6",
language = "English (US)",
volume = "6",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

Sullivan, RJ, Atkins, MB, Kirkwood, JM, Agarwala, SS, Clark, JI, Ernstoff, MS, Fecher, L, Gajewski, TF, Gastman, B, Lawson, DH, Lutzky, J, McDermott, DF, Margolin, KA, Mehnert, JM, Pavlick, AC, Richards, JM, Rubin, KM, Sharfman, W, Silverstein, S, Slingluff, CL, Sondak, VK, Tarhini, AA, Thompson, JA, Urba, WJ, White, RL, Whitman, E, Hodi, FS & Kaufman, HL 2018, 'An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: Version 2.0', Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, 44. https://doi.org/10.1186/s40425-018-0362-6

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma : Version 2.0. / Sullivan, Ryan J.; Atkins, Michael B.; Kirkwood, John M.; Agarwala, Sanjiv S.; Clark, Joseph I.; Ernstoff, Marc S.; Fecher, Leslie; Gajewski, Thomas F.; Gastman, Brian; Lawson, David H.; Lutzky, Jose; McDermott, David F.; Margolin, Kim A.; Mehnert, Janice M.; Pavlick, Anna C.; Richards, Jon M.; Rubin, Krista M.; Sharfman, William; Silverstein, Steven; Slingluff, Craig L.; Sondak, Vernon K.; Tarhini, Ahmad A.; Thompson, John A.; Urba, Walter J.; White, Richard L.; Whitman, Eric; Hodi, F. Stephen; Kaufman, Howard L.

In: Journal for ImmunoTherapy of Cancer, Vol. 6, No. 1, 44, 30.05.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma

T2 - Version 2.0

AU - Sullivan, Ryan J.

AU - Atkins, Michael B.

AU - Kirkwood, John M.

AU - Agarwala, Sanjiv S.

AU - Clark, Joseph I.

AU - Ernstoff, Marc S.

AU - Fecher, Leslie

AU - Gajewski, Thomas F.

AU - Gastman, Brian

AU - Lawson, David H.

AU - Lutzky, Jose

AU - McDermott, David F.

AU - Margolin, Kim A.

AU - Mehnert, Janice M.

AU - Pavlick, Anna C.

AU - Richards, Jon M.

AU - Rubin, Krista M.

AU - Sharfman, William

AU - Silverstein, Steven

AU - Slingluff, Craig L.

AU - Sondak, Vernon K.

AU - Tarhini, Ahmad A.

AU - Thompson, John A.

AU - Urba, Walter J.

AU - White, Richard L.

AU - Whitman, Eric

AU - Hodi, F. Stephen

AU - Kaufman, Howard L.

PY - 2018/5/30

Y1 - 2018/5/30

N2 - Background: Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patients with melanoma. However, prospective data to support evidence-based clinical decisions with respect to the optimal schedule and sequencing of immunotherapy and targeted agents, how best to manage emerging toxicities and when to stop treatment are not yet available. Methods: To address this knowledge gap, the Society for Immunotherapy of Cancer (SITC) Melanoma Task Force developed a process for consensus recommendations for physicians treating patients with melanoma integrating evidence-based data, where available, with best expert consensus opinion. The initial consensus statement was published in 2013, and version 2.0 of this report is an update based on a recent meeting of the Task Force and extensive subsequent discussions on new agents, contemporary peer-reviewed literature and emerging clinical data. The Academy of Medicine (formerly Institute of Medicine) clinical practice guidelines were used as a basis for consensus development with an updated literature search for important studies published between 1992 and 2017 and supplemented, as appropriate, by recommendations from Task Force participants. Results: The Task Force considered patients with stage II-IV melanoma and here provide consensus recommendations for how they would incorporate the many immunotherapy options into clinical pathways for patients with cutaneous melanoma. Conclusion: These clinical guidleines provide physicians and healthcare providers with consensus recommendations for managing melanoma patients electing treatment with tumor immunotherapy.

AB - Background: Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patients with melanoma. However, prospective data to support evidence-based clinical decisions with respect to the optimal schedule and sequencing of immunotherapy and targeted agents, how best to manage emerging toxicities and when to stop treatment are not yet available. Methods: To address this knowledge gap, the Society for Immunotherapy of Cancer (SITC) Melanoma Task Force developed a process for consensus recommendations for physicians treating patients with melanoma integrating evidence-based data, where available, with best expert consensus opinion. The initial consensus statement was published in 2013, and version 2.0 of this report is an update based on a recent meeting of the Task Force and extensive subsequent discussions on new agents, contemporary peer-reviewed literature and emerging clinical data. The Academy of Medicine (formerly Institute of Medicine) clinical practice guidelines were used as a basis for consensus development with an updated literature search for important studies published between 1992 and 2017 and supplemented, as appropriate, by recommendations from Task Force participants. Results: The Task Force considered patients with stage II-IV melanoma and here provide consensus recommendations for how they would incorporate the many immunotherapy options into clinical pathways for patients with cutaneous melanoma. Conclusion: These clinical guidleines provide physicians and healthcare providers with consensus recommendations for managing melanoma patients electing treatment with tumor immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85047920993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047920993&partnerID=8YFLogxK

U2 - 10.1186/s40425-018-0362-6

DO - 10.1186/s40425-018-0362-6

M3 - Article

VL - 6

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 44

ER -